The A-T Children’s Project is excited to be hosting an international conference in November dedicated to addressing gene therapy for ataxia-telangiectasia (A-T). This conference will bring together academic scientists, clinicians and industry leaders in the biotech and pharmaceutical sectors who are pioneering DNA replacement and editing approaches. Researchers using viral vectors, antisense oligonucleotides (ASOs), lipid nanoparticles (LNPs), CRISPR, tRNA, base editing, and other cutting-edge technologies are encouraged to attend.
The in-person meeting will feature discussions on current efforts to treat A-T using ASOs and evaluate other emerging gene editing and replacement technologies. Attendees will share late-breaking data, explore the potential of new technologies and modalities, discuss fluid biomarkers and other translational tools, compare innovative clinical trial designs and hopefully form new collaborations to accelerate progress.
Participation is limited to the scientific community and industry experts.